Biomed Central Ltd

SHERPA: Unknown

People

  1. Voss
    Voss
  2. Motzer
    Motzer
  3. Kotecha
    Kotecha
  4. Carlo
    Carlo
  5. Hakimi
    Hakimi
  6. Chen
    Chen
  7. Coleman
    Coleman
  8. Feldman
    Feldman
  9. Iyer
    Iyer
  10. Knezevic
    Knezevic

Groups

  1. Department of Medicine (15)
  2. Genitourinary Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Hematology-Oncology Fellows (7)
  5. Weinberg Fellows (7)
  6. Epidemiology and Biostatistics (6)
  7. Hematologic Malignancies, Division of (6)
  8. Biostatistics Service (5)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  10. GSK Faculty (3)
Search Within
  1. "Martin Voss"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (3)
  3. Guidelines (1)
Groups
  1. Department of Medicine (15)
  2. Genitourinary Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Hematology-Oncology Fellows (7)
  5. Weinberg Fellows (7)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. Martin Voss (15)
  2. Robert Motzer (5)
  3. Chung-Han Lee (4)
  4. Ritesh Kotecha (4)
  5. Abraham Hakimi (3)
  6. Maria Carlo (3)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (3)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (3)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (12)
  2. BMC Urology (1)
  3. Genome Biology (1)
  4. Genome Medicine (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Journal Article

    Mantia, C. M.; Jegede, O. A.; Plimack, E. R.; Powles, T.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape
    Journal Article

    Golkaram, M.; Kuo, F.; Gupta, S.; Carlo, M. I.; Salmans, M. L.; Vijayaraghavan, R.; Tang, C.; Makarov, V.; Rappold, P.; Blum, K. A.; more...
    Genome Medicine (2022)

    Fulltext@MSK | Save
  • Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma
    Meeting Abstract

    Choueiri, T.; Plimack, E.; Powles, T.; Voss, M.; Gurney, H.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Rini, B.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • In silico modeling of combination systemic therapy for advanced renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Hsu, D. J.; Lee, C. H.; Patil, S.; Voss, M. H.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
    Journal Article

    Ged, Y.; Gupta, R.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    BMC Urology (2020)

    Fulltext@MSK | Save
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
    Guidelines

    Rini, B. I.; Battle, D.; Figlin, R. A.; George, D. J.; Hammers, H.; Hutson, T.; Jonasch, E.; Joseph, R. W.; McDermott, D. F.; Motzer, R. J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
    Journal Article

    Boilève, A.; Carlo, M. I.; Barthélémy, P.; Oudard, S.; Borchiellini, D.; Voss, M. H.; George, S.; Chevreau, C.; Landman-Parker, J.; Tabone, M. D.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study
    Journal Article

    Amin, A.; Plimack, E. R.; Ernstoff, M. S.; Lewis, L. D.; Bauer, T. M.; McDermott, D. F.; Carducci, M.; Kollmannsberger, C.; Rini, B. I.; Heng, D. Y. C.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save